Spitalul Clinic Municipal De Urgenta Timisoara — Clinical Trial Site

29 Registered trials

20 Currently recruiting

Organisation

Spitalul Clinic Municipal De Urgenta Timisoara

Location

Timisoara, Romania

Identifier

ORG-100042881

Address

Strada Dima Gheorghe Nr.5, 300079, Romania

Departments

#2115: Hematology
#3231: Cardiology
#7055 - Hematology
3001: Hematology
8617: Internal Medicine
8620: Cardiology
Cardiologie
Cardiology
Cardiology Clinic
Cardiology Clinic-ASCAR
Cardiology II
Cardiology/ Internal Medicine
Clinica de Cardiologie – ASCAR
Clinica de Hematologie
Clinica de Medicina Interna
Haematology
Hematology
Hematology department
Internal Medicine
Medical Oncology
Medicina Interna
N/A
Sectia Clinica de Medicina Interna

Clinical trials at this site (29)

Search interface

A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Unknown

2022-502779-40-99 Primary prevention of atherosclerotic cardiovascular di 5
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia Recruiting

2025-524810-28-00 Acute Promyelocytic Leukemia 5 2026-07-02
A phase 2/3, multi-center, study of L-Annamycin in combination with cytarabine vs. placebo in combination with cytarabine as second line the… Recruiting

2024-518359-47-00 Acute Myeloid Leukemia 10 2025-06-17
A Multicenter, Open-Label, Dose-Finding, Phase 2 Study Evaluating THIO Sequenced with Cemiplimab (LIBTAYO®) in Subjects with Advanced Non-Sm… Recruiting

2023-504595-26-00 Non-Small Cell Lung Cancer 4 2023-05-22
ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting

2025-522960-34-00 Established cardiovascular disease 5 2026-02-09
A Multicenter, Open-label, Randomized Phase 3 Study Evaluating THIO Sequenced with Cemiplimab (LIBTAYO®) vs Investigator Choice of Single-ag… Recruiting

2024-520164-33-00 Non-Small Cell Lung Cancer 5 2025-12-09
FORTIFY – Focused Orticumab Research for Treating inflammation in Coronary Arteries Recruiting

2025-520464-17-00 Atherosclerotic Cardiovascular disease 4 2025-10-21
A Trial to Test How AZD0780 Affects Serious Heart, Stroke, or Vascular Problems in Patients with Heart, Stroke or Vascular Disease or at Hig… Recruiting

2025-520519-14-00 Atherosclerotic Cardiovascular Disease 5 2025-09-03
A study to test whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure and a weak pumping functio… Recruiting

2024-519525-38-00 Heart failure 5 2025-08-22
A phase III, randomized, open-label, blinded endpoint, comparative trial of ferric derisomaltose versus no intravenous iron in iron-deficien… Recruiting

2024-519059-28-00 Chronic Heart Failure 5 2025-07-17
202301CPC Redefine-HF Recruiting

2023-508581-15-00 Heart condition 5 2024-10-08
Clinical trial comparing MK-2870 given with pembrolizumab to pembrolizumab alone in participants who have had surgery for NSCLC Recruiting

2023-508012-35-00 Newly diagnosed NSCLC with resectable clinical Stage II 5 2024-10-02
A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Lisaftoclax (APG-2575) in Previously Treated Patients with Chro… Recruiting

2023-508005-24-00 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 5 2024-08-01
Phase III study to evaluate the effect of balcinrenone/dapagliflozin in patients with heart failure and impaired kidney function Recruiting

2023-508162-15-00 Chronic HF and comorbid impairment of kidney function w 5 2024-07-12
A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerabilit… Recruiting

2023-504835-42-00 Heart Failure (Heart Failure with Reduced Ejection Frac 4 2024-02-29
A Randomized, Multi-Center, Parallel, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics o… Recruiting

2022-502193-16-00 Chronic lymphocytic leukemia, Multiple Myeloma and Non- 5 2023-11-14
A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaLuate the effIcacy and safety of abeLacimab… Recruiting

2023-503224-66-00 Atrial Fibrillation 5 2023-10-31
Asciminib Roll-over Study Recruiting

2023-507557-16-00 chronic myelogenous leukemia (CML) or Philadelphia Chro 5 2022-08-31
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Ended

2022-502779-40-00 Primary prevention of atherosclerotic cardiovascular di 5 2023-09-04
OCEAN(a)-Outcomes – Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction – Outcomes trial Ended

2022-501608-85-00 Cardiovascular disease (atherosclerotic cardiovascular 5 2023-05-09
HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation. Ended

2022-501939-16-00 Heart failure (HF) with mildly reduced ejection fractio 5 2023-05-09
A phase 3, randomized, double- blind, study of ianalumab (VAY736) versus placebo in addition to eltrombopag in primary immune thrombocytopen… Ended

2024-512890-28-00 Primary immune thrombocytopenia (ITP) 5 2023-03-20
A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With N… Ended

2024-510947-71-00 Chronic Myeloid Leukemia 5 2022-11-21
A research study to find out whether a medicine called inclisiran helps to prevent cardiovascular death, heart attacks or strokes in people … Ended

2024-510735-21-00 Atherosclerotic cardiovascular disease (ASCVD) 5 2021-11-26